Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MAXZIDE AND DYAZIDE COMPARATIVE DOSAGES

Executive Summary

Reproduced by "The Pink Sheet" from initial labeling for Maxzide and most recent PDR labeling version for Dyazide. MAXZIDE DOSAGE AND ADMINISTRATION -- The recommended dosage of MAZXIDE is one tablet daily with appropriate monitoring of serum potassium levels (see WARNINGS). Patients receiving 50 mg of hydrochlorothiazide who become hypokalemic may be transferred to MAXZIDE directly. In patients requiring 50 mg of hydrochlorothiazide in whom hypokalemia cannot be risked, therapy may be initiated with MAXZIDE. There is no clinical experience with doses exceeding one tablet daily. Clinical studies have shown that patients already taking less bioavailable formulations of triamterene and hydrochlorothiazide (totaling 50-100 mg of hydrochlorothiazide and 100-200 mg of triamterene) may be safely changed to one MAXZIDE tablet per day.; these patients should be monitored clinically and with serum potassium after the transfer. DYAZIDE DOSAGE AND ADMINISTRATION -- As determined by individual titration. Adults: The usual dose is one or two capsules twice daily after meals. Some patients may be maintained on one capsule daily or every other day. Maximum daily dose should not exceed four capsules, and at this dosage, the incidence of side effects may increase. Since 'Dyazide' has an antihypertensive effect, hypotensive drugs used concomitantly should be added at reduced dosage -- at least one half the usual dosage -- particularly if it is a ganglionic or peripheral adrenergic blocking agent. Adjust dosage as indicated. Children: Adequate information on the use of 'Dyazide' in children is not available. Note: Potassium supplementation used concurrently with other diuretics should be discontinued when titrating with Dyrenium (triamterene, SK&F Co.). They should not be reinstituted when the patient is placed on 'Dyazide' unless the triamterene component does not completely compensate for the potassium loss.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS007393

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel